Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.52 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415984 | 0.92 | MAP1LC3B (0.50) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL10965567 | 0.87 | WDR5 (0.55) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL15945996 | 0.85 | MAP1LC3B (0.53) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL2151217 | 0.83 | THRA (0.50) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL9491401 | 0.82 | THRA (0.58) | AURKAKDRAURKBBRD4ALDH1A1 | |
| SCHEMBL11396218 | 0.82 | ALDH1A1 (0.58) | MAP1LC3BMAP1LC3AALDH1A1SMN1; SMN2THRA | |
| SCHEMBL27846668 | 0.82 | WDR5 (0.53) | POLBWDR5 | |
| SCHEMBL9848235 | 0.81 | THRA (0.48) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL9848239 | 0.81 | THRA (0.48) | MAP1LC3BMAP1LC3AAURKAKDRAURKB | |
| SCHEMBL6301508 | 0.80 | AURKA (0.53) | MAP1LC3BMAP1LC3AAURKAKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | MAP1LC3B 2324/4885MAP1LC3A 2063/4885AURKA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.